Top-Rated StocksTop-RatedNASDAQ:PLRX Pliant Therapeutics (PLRX) Stock Forecast, Price & News $22.88 -0.21 (-0.91%) (As of 11:21 AM ET) Add Compare Share Share Today's Range$22.66▼$23.2450-Day Range$20.99▼$30.5652-Week Range$6.37▼$36.64Volume50,822 shsAverage Volume809,388 shsMarket Capitalization$1.35 billionP/E RatioN/ADividend YieldN/APrice Target$47.83 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Pliant Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside107.2% Upside$47.83 Price TargetShort InterestBearish10.41% of Shares Sold ShortDividend StrengthN/ASustainability-0.73Upright™ Environmental ScoreNews Sentiment1.20Based on 3 Articles This WeekInsider TradingSelling Shares$1.71 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.99) to ($3.40) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.40 out of 5 starsMedical Sector172nd out of 981 stocksPharmaceutical Preparations Industry75th out of 484 stocks 4.5 Analyst's Opinion Consensus RatingPliant Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 11 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $47.83, Pliant Therapeutics has a forecasted upside of 107.2% from its current price of $23.09.Amount of Analyst CoveragePliant Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.41% of the outstanding shares of Pliant Therapeutics have been sold short.Short Interest Ratio / Days to CoverPliant Therapeutics has a short interest ratio ("days to cover") of 8.7.Change versus previous monthShort interest in Pliant Therapeutics has recently increased by 48.43%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPliant Therapeutics does not currently pay a dividend.Dividend GrowthPliant Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePliant Therapeutics has received a 74.73% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Pliant Therapeutics is -0.73. Previous Next 2.3 News and Social Media Coverage News SentimentPliant Therapeutics has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Pliant Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for PLRX on MarketBeat in the last 30 days. This is a decrease of -94% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Pliant Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pliant Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,705,880.00 in company stock.Percentage Held by InsidersOnly 5.60% of the stock of Pliant Therapeutics is held by insiders.Percentage Held by Institutions97.52% of the stock of Pliant Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Pliant Therapeutics are expected to decrease in the coming year, from ($2.99) to ($3.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pliant Therapeutics is -8.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pliant Therapeutics is -8.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPliant Therapeutics has a P/B Ratio of 3.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Pliant Therapeutics (NASDAQ:PLRX) StockPliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.Read More Receive PLRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pliant Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PLRX Stock News HeadlinesJune 5, 2023 | finance.yahoo.comInvestors in Pliant Therapeutics (NASDAQ:PLRX) have seen splendid returns of 253% over the past yearJune 2, 2023 | americanbankingnews.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Recommendation of "Buy" from AnalystsJune 8, 2023 | Edge On The Street (Ad)Graphite Shortage Could Derail the $7 Trillion EV TransitionGraphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.May 25, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Pliant Therapeutics (PLRX)May 24, 2023 | markets.businessinsider.comStifel Nicolaus Sticks to Their Buy Rating for Pliant Therapeutics (PLRX)May 24, 2023 | finance.yahoo.comPliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International ConferenceMay 23, 2023 | seekingalpha.comPliant Therapeutics: Trading In Oversold Territory, Buying The DipMay 22, 2023 | americanbankingnews.comCanaccord Genuity Group Initiates Coverage on Pliant Therapeutics (NASDAQ:PLRX)June 8, 2023 | Edge On The Street (Ad)Graphite Shortage Could Derail the $7 Trillion EV TransitionGraphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.May 20, 2023 | americanbankingnews.comPliant Therapeutics (NASDAQ:PLRX) Shares Gap Up to $21.53May 17, 2023 | americanbankingnews.comBrokers Offer Predictions for Pliant Therapeutics, Inc.'s FY2023 Earnings (NASDAQ:PLRX)May 17, 2023 | americanbankingnews.comPliant Therapeutics (NASDAQ:PLRX) Stock Rating Reaffirmed by Cantor FitzgeraldMay 16, 2023 | markets.businessinsider.comStifel Nicolaus Sticks to Its Buy Rating for Pliant Therapeutics (PLRX)May 16, 2023 | americanbankingnews.comBrokers Offer Predictions for Pliant Therapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:PLRX)May 12, 2023 | msn.comRBC Capital Maintains Pliant Therapeutics (PLRX) Outperform RecommendationMay 12, 2023 | americanbankingnews.comHC Wainwright Trims Pliant Therapeutics (NASDAQ:PLRX) Target Price to $50.00May 11, 2023 | msn.comOppenheimer Maintains Pliant Therapeutics (PLRX) Outperform RecommendationMay 11, 2023 | markets.businessinsider.comSVB Securities Keeps Their Buy Rating on Pliant Therapeutics (PLRX)May 11, 2023 | americanbankingnews.comPliant Therapeutics (NASDAQ:PLRX) Price Target Raised to $51.00 at OppenheimerMay 10, 2023 | msn.comRecap: Pliant Therapeutics Q1 EarningsMay 10, 2023 | markets.businessinsider.comBTIG Reaffirms Their Buy Rating on Pliant Therapeutics (PLRX)May 10, 2023 | finanznachrichten.dePliant Therapeutics, Inc.: Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial ResultsMay 9, 2023 | finance.yahoo.comPliant Therapeutics, Inc. (PLRX) Reports Q1 Loss, Misses Revenue EstimatesMay 9, 2023 | finance.yahoo.comPliant Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial ResultsMay 6, 2023 | americanbankingnews.comFY2023 EPS Estimates for Pliant Therapeutics, Inc. (NASDAQ:PLRX) Raised by AnalystMay 6, 2023 | americanbankingnews.comBrokerages Set Pliant Therapeutics, Inc. (NASDAQ:PLRX) PT at $47.64May 5, 2023 | americanbankingnews.comResearch Analysts Issue Forecasts for Pliant Therapeutics, Inc.'s Q1 2023 Earnings (NASDAQ:PLRX)See More Headlines PLRX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PLRX Company Calendar Last Earnings5/09/2023Today6/08/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PLRX CUSIPN/A CIK1746473 Webpliantrx.com Phone650-481-6770FaxN/AEmployees91Year FoundedN/APrice Target and Rating Average Stock Price Forecast$47.83 High Stock Price Forecast$63.00 Low Stock Price Forecast$33.00 Forecasted Upside/Downside+107.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($2.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-123,320,000.00 Net Margins-1,359.22% Pretax Margin-1,359.22% Return on Equity-39.05% Return on Assets-35.16% Debt Debt-to-Equity Ratio0.02 Current Ratio25.41 Quick Ratio25.41 Sales & Book Value Annual Sales$9.69 million Price / Sales140.97 Cash FlowN/A Price / Cash FlowN/A Book Value$6.43 per share Price / Book3.59Miscellaneous Outstanding Shares59,160,000Free Float55,843,000Market Cap$1.37 billion OptionableNot Optionable Beta1.40 Key ExecutivesDr. Bernard Coulie M.B.A. (Age 56)M.D., MBA, Ph.D., Pres, CEO & Director Comp: $889.01kDr. Keith Lamont Cummings M.B.A. (Age 45)M.D., Chief Financial Officer Comp: $606.12kMr. Mike Ouimette (Age 49)Gen. Counsel & Corp. Sec. Comp: $537.99kMr. Johannes P. Hull (Age 47)Chief Bus. Officer Comp: $582.49kDr. Éric Lefebvre M.D. (Age 58)Chief Medical Officer Comp: $713.81kDr. Rik DerynckScientific Founder & Member of Scientific Advisory BoardMr. Dean Sheppard M.D.Scientific Founder & Member of Scientific Advisory BoardMr. Bill DeGrado Ph.D.Scientific Founder & Member of Scientific Advisory BoardMr. Hal Chapman M.D.Scientific Founder & Member of Scientific Advisory BoardMr. Craig D. MuirInterim Chief Technology OfficerMore ExecutivesKey CompetitorsIDEAYA BiosciencesNASDAQ:IDYATravere TherapeuticsNASDAQ:TVTXKeros TherapeuticsNASDAQ:KROSBiomea FusionNASDAQ:BMEATaro Pharmaceutical IndustriesNYSE:TAROView All CompetitorsInsiders & InstitutionsJPMorgan Chase & Co.Bought 200,200 shares on 5/18/2023Ownership: 0.000%New York State Common Retirement FundBought 2,150 shares on 5/18/2023Ownership: 0.038%State Street CorpBought 29,276 shares on 5/16/2023Ownership: 0.490%Squarepoint Ops LLCBought 19,852 shares on 5/16/2023Ownership: 0.082%Balyasny Asset Management L.P.Sold 22,454 shares on 5/16/2023Ownership: 0.018%View All Insider TransactionsView All Institutional Transactions PLRX Stock - Frequently Asked Questions Should I buy or sell Pliant Therapeutics stock right now? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pliant Therapeutics in the last year. There are currently 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PLRX shares. View PLRX analyst ratings or view top-rated stocks. What is Pliant Therapeutics' stock price forecast for 2023? 11 brokers have issued 1-year price objectives for Pliant Therapeutics' shares. Their PLRX share price forecasts range from $33.00 to $63.00. On average, they predict the company's share price to reach $47.83 in the next twelve months. This suggests a possible upside of 107.2% from the stock's current price. View analysts price targets for PLRX or view top-rated stocks among Wall Street analysts. How have PLRX shares performed in 2023? Pliant Therapeutics' stock was trading at $19.33 at the beginning of the year. Since then, PLRX stock has increased by 19.5% and is now trading at $23.09. View the best growth stocks for 2023 here. Are investors shorting Pliant Therapeutics? Pliant Therapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 6,160,000 shares, an increase of 48.4% from the April 30th total of 4,150,000 shares. Based on an average daily volume of 708,200 shares, the short-interest ratio is presently 8.7 days. View Pliant Therapeutics' Short Interest. When is Pliant Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our PLRX earnings forecast. How were Pliant Therapeutics' earnings last quarter? Pliant Therapeutics, Inc. (NASDAQ:PLRX) issued its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.66) by $0.01. The business earned $1.33 million during the quarter, compared to analyst estimates of $1.96 million. Pliant Therapeutics had a negative trailing twelve-month return on equity of 39.05% and a negative net margin of 1,359.22%. What ETFs hold Pliant Therapeutics' stock? ETFs with the largest weight of Pliant Therapeutics (NASDAQ:PLRX) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), iShares U.S. Pharmaceuticals ETF (IHE), iShares Micro-Cap ETF (IWC), BlackRock Future Health ETF (BMED) and Invesco Nasdaq Biotechnology ETF (IBBQ). What other stocks do shareholders of Pliant Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pliant Therapeutics investors own include Pfizer (PFE), Ampio Pharmaceuticals (AMPE), CrowdStrike (CRWD), Trevena (TRVN), AbbVie (ABBV), Abbott Laboratories (ABT), Archer-Daniels-Midland (ADM), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD) and Applied DNA Sciences (APDN). When did Pliant Therapeutics IPO? (PLRX) raised $90 million in an initial public offering (IPO) on Wednesday, June 3rd 2020. The company issued 6,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Piper Sandler served as the underwriters for the IPO and Needham & Company was co-manager. What is Pliant Therapeutics' stock symbol? Pliant Therapeutics trades on the NASDAQ under the ticker symbol "PLRX." Who are Pliant Therapeutics' major shareholders? Pliant Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (7.66%), CHI Advisors LLC (5.07%), Price T Rowe Associates Inc. MD (3.56%), BlackRock Inc. (3.09%), First Light Asset Management LLC (2.41%) and Jennison Associates LLC (2.08%). Insiders that own company stock include Bernard Coulie, Eric Lefebvre, Keith Lamont Cummings, Matthew Dunnigan and Mike Ouimette. View institutional ownership trends. How do I buy shares of Pliant Therapeutics? Shares of PLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Pliant Therapeutics' stock price today? One share of PLRX stock can currently be purchased for approximately $23.09. How much money does Pliant Therapeutics make? Pliant Therapeutics (NASDAQ:PLRX) has a market capitalization of $1.37 billion and generates $9.69 million in revenue each year. The company earns $-123,320,000.00 in net income (profit) each year or ($2.86) on an earnings per share basis. How can I contact Pliant Therapeutics? Pliant Therapeutics' mailing address is 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is pliantrx.com. The company can be reached via phone at 650-481-6770 or via email at ir@pliantrx.com. This page (NASDAQ:PLRX) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pliant Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.